INDOCO

- Promoter Suresh G Kare acquired 1,335 equity shares of Indoco Remedies Limited from the open market. - Date of acquisition was November 6, 2026. - Post-acquisition shareholding increased from 13,12,045 shares (1.421%) to 13,13,380 shares (1.423%).

Current Scenario & Performance - Q2 FY27 consolidated revenue crossed the ₹500 Cr milestone at ₹506.9 Cr, up 7.4% YoY. - Operating margins were impacted by elevated freight expenses (~₹13 Cr impact) and higher raw material costs. - Regulated markets grew 21.1% YoY to ₹110.9 Cr, with strong performance in the UK, Europe, and US. - Domestic formulations declined to ₹212.8 Cr as acute/seasonal therapies faced headwinds, though flagship brand Cyclopam crossed ₹200 Cr sales. Management Guidance & Outlook - Targeting high single-digit growth for the domestic formulation business in FY27. - Regulated export markets targeted to grow at 20%+ over the next 1-2 years, with emerging markets expected to recover in H2. - R&D expenditure will be managed at under 5% of revenue. Capex & Debt - Tangible Capex to remain minimal at under ₹25 Cr for the year, with low Capex expected for FY28. - Repaid ~₹65 Cr of consolidated debt in H1 FY27 and remains on track to meet annual debt repayment targets. Regulatory & Strategic Updates - Goa Plant-1 cleared MHRA audit and AnaCipher CRO cleared ANVISA inspection; USFDA audit responses submitted with clarity expected by early December. - Incorporated Warren Life Sciences to separately manage and streamline OTC and API operations.

- Audio recording of the Earnings Conference Call for Q2 and H1 FY27 results held on October 27, 2026, is available on the Company's website. - The call concluded at 04:05 p.m. (IST).

- Indoco Remedies' Clinical Research Organisation, AnaCipher, received approval from ANVISA Brazil for its clinical and bioanalytical facilities. - The approval authorizes AnaCipher to conduct Bioavailability and Bioequivalence studies for submission to Brazil. - The inspection by ANVISA was conducted from March 30, 2026, to April 7, 2026. - This development strengthens AnaCipher's international regulatory footprint and expands its capabilities in Latin America.

Q2 FY27 Consolidated Revenue ₹506.92 Cr vs ₹471.83 Cr (▲7.4% YoY) EBITDA ₹46.43 Cr vs ₹43.10 Cr (▲7.7% YoY) PAT ₹19.47 Cr vs -₹9.24 Cr (Turnaround from Net Loss YoY) EBITDA Margin 9.2% vs 9.1% (▲10bps)

- Indoco Remedies Limited has approved the allotment of 14,850 equity shares of face value ₹2 each under the Employee Stock Option Plan – 2022. - The shares are allotted to the Indoco Employees Welfare Trust. - Paid-up capital increased from ₹18,46,07,210 to ₹18,46,36,910.

Concall Schedule Concall Date: October 27, 2026 Concall Time: 03:00 P.M. IST

- Indoco Remedies has issued a reminder to shareholders holding shares in physical mode to furnish mandatory PAN, KYC, mobile number, signature, and bank details. - The intimation complies with SEBI Master Circular dated February 6, 2026. - Shareholders are requested to submit the required forms to the RTA, MUFG Intime India Private Limited.

- Indoco Remedies Limited has incorporated a wholly owned subsidiary named "Warren Lifesciences Private Limited" on 26th September, 2026. - The new subsidiary will operate in the pharmaceutical sector, focusing on manufacturing, developing, and selling pharmaceutical products, APIs, and formulations. - Indoco Remedies will hold 100% of the paid-up share capital, subscribing to 10,000 equity shares at face value via cash consideration.

- Trading window closed from October 1, 2026, until 48 hours after Q2/H1 FY27 financial results declaration. - Applies to designated persons and their immediate relatives. - Board meeting date for financial results to be intimated later.

- Indoco Remedies Limited has been assigned an ESG rating of "Crisil ESG 60" by Crisil ESG Ratings & Analytics Limited. - The rating was independently prepared using publicly available information, as the company did not engage the agency for this rating.

- Indoco Remedies Limited approved the incorporation of a wholly-owned subsidiary, 'Warren Lifesciences Private Limited'. - The subsidiary will focus on manufacturing, developing, and selling pharmaceutical products, including APIs and formulations. - It will be 100% owned by Indoco Remedies, with a paid-up capital of ₹1,00,000.

- UK MHRA inspected Indoco Remedies' Goa manufacturing facility (Plant I) from September 7-9, 2026. - The inspection concluded with no critical or major observations, validating the company's quality systems and regulatory compliance.

- USFDA inspected Indoco Remedies' Goa Plant II (Sterile) facility from August 27 to September 4, 2026. - The company received seven (7) observations in Form 483. - Indoco Remedies will address the observations and respond to the USFDA.

- Indoco Remedies Limited executed the sale of a 2,876.08 sq. meters land parcel on August 27, 2026, to Kalpataru Townships Private Limited. - The transaction was for a consideration of ₹64 Crore (₹640,000,000/-). - This sale is not expected to impact the company's business operations.

- Filed Business Responsibility and Sustainability Report (BRSR) for FY 2025-2026. - Sets ESG targets for FY25-26, including 3% reduction in freshwater, energy, and GHG emissions. - Commits to zero workplace incidents, human rights violations, data breaches, corruption, and bribery.

- Indoco Remedies Limited announced the Record Date for the final dividend of Rs. 0.20 per equity share for FY ended March 31, 2026, as September 10, 2026. Book Closure will be from September 11 to 17, 2026. The 79th Annual General Meeting (AGM) will be held on September 17, 2026.

- Management guided for a 12-15% sales CAGR over the next few years and expects EBITDA margins to keep improving quarter-on-quarter, targeting double-digit margins for FY27. - FY27 Capex is limited to maintenance, not exceeding INR40-50 crores. - The company plans to repay INR260 crores of debt within the next 7-18 months, having already reduced overall debt to INR930 crores. - India business is projected to achieve higher single-digit to double-digit growth. - Gross margins were impacted by 200bps in Q1 due to raw material costs, with normalization expected by Q3. - The US sterile business profitability and new product approvals are on hold pending an awaited USFDA audit; management hopes for an early audit. - Operational efficiencies led to a reduction of approximately 900 employees and 26% fewer batches for equivalent sales. - Strong regulatory clearances were received for Baddi Unit I (Malta), Baddi Unit III (EU-GMP), and Goa plant I (Malta), and a USFDA pre-approval inspection for Indoco Stability Center had 0 observations.

- Audio recording and transcript of the earnings conference call on Unaudited Standalone and Consolidated Financial Results for the Quarter Ended June 30, 2026, held on July 28, 2026, are available on the company's website.

- Ms. Aditi Panandikar (DIN: 00179113) re-appointed as Managing Director for 5 years, effective Feb 15, 2027, to Feb 14, 2032, subject to shareholder approval. - Mr. Sudhir Kadam appointed as Senior Management Personnel, designated as Sr. Vice President (Human Capital), with effect from July 28, 2026.

- Board of Directors re-appointed Ms. Aditi Panandikar as Managing Director for a period of 5 years (February 15, 2027, to February 14, 2032), subject to shareholder approval. - Mr. Sudhir Kadam was appointed as Sr. Vice President (Human Capital) with effect from July 28, 2026.

- Consolidated Revenue ₹46,622 Lakhs vs ₹43,086 Lakhs (▲8.2% YoY) - EBITDA ₹4,002 Lakhs vs ₹1,753 Lakhs (▲128.3% YoY) - PAT ₹6,544 Lakhs vs ₹(3,635) Lakhs (Turned from loss to profit, ▲280.0% YoY) - EBITDA Margin 8.58% vs 4.07% (▲451bps)

- Concall Schedule - Concall Date: Tuesday, 28th July, 2026 - Concall Time: 03:30 P.M. IST

- Trading window to remain closed from July 01, 2026, until 48 hours after the declaration of financial results for the Quarter Ended June 30, 2026.

- Indoco Remedies' Goa Plant I received EU GMP certification from the Malta Medicines Authority following an inspection from November 19-24, 2025. - The certification confirms the facility's compliance with Good Manufacturing Practice requirements.

- Notice for transfer of unclaimed equity shares and dividends (Final Dividend 2018-19) to the Investor Education and Protection Fund (IEPF), pursuant to Section 124(6) of Companies Act, 2013. - Shareholders must claim dividends by October 03, 2026, to avoid transfer of shares and unclaimed dividends.